1-methyl-3-isobutylxanthine has been researched along with Diabetes Mellitus, Type 1 in 4 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with IDDM had increased platelet aggregation (PA, expressed as microM ADP threshold concentration) before Rd was detectable in comparison to control subjects (P less than 0." | 1.27 | Platelet enzyme activities in diabetes mellitus in relation to endothelial damage. ( Janka, HU; Mehnert, H; Schramm, W; Standl, E, 1983) |
| "In human IDDM, similar abnormalities to those seen in the BB model were observed." | 1.27 | Platelets and vascular smooth muscle: abnormalities of phosphodiesterase, aggregation, and cell growth in experimental and human diabetes. ( Franks, DJ; Hamet, P; Sugimoto, H; Umeda, F, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janka, HU | 1 |
| Standl, E | 1 |
| Schramm, W | 1 |
| Mehnert, H | 1 |
| Hamet, P | 1 |
| Sugimoto, H | 1 |
| Umeda, F | 1 |
| Franks, DJ | 1 |
| Chen, MC | 1 |
| Proost, P | 1 |
| Gysemans, C | 1 |
| Mathieu, C | 1 |
| Eizirik, DL | 1 |
| Weir, GC | 1 |
| Leahy, JL | 1 |
| Bonner-Weir, S | 1 |
1 review available for 1-methyl-3-isobutylxanthine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Arginine; Blood Glucose; Cyclic AMP; Diabete | 1986 |
3 other studies available for 1-methyl-3-isobutylxanthine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Platelet enzyme activities in diabetes mellitus in relation to endothelial damage.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Diphosphate; Adenylyl Cyclases; Adolescent; Adult; Aged; beta | 1983 |
Platelets and vascular smooth muscle: abnormalities of phosphodiesterase, aggregation, and cell growth in experimental and human diabetes.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterase | 1983 |
Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Type 1; Fe | 2001 |